# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Oren Livnat reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $94 price ...
Revised Full Year 2024 Guidance:The following guidance for 2024 does not include contribution from the pending acquisition of A...
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food a...
HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price targ...